US › Healthcare

Tenax Therapeutics Inc (TENX)

US · Healthcare · Biotechnology

$1.36-9.93%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-17.8M

EPS

$-0.35

EPS estimate

$-0.38

EPS came in at -0.35 against a street estimate of -0.38 — a beat of 7.9%.

Key statistics

Market cap

$59.9M

Forward P/E

0.3

P/B

0.63

Book value

$2.19

EPS (TTM)

$-1.48

52-week high

$19.40

52-week low

$1.31

50-day MA

$2.79

200-day MA

$10.83

Beta

0.92

Analyst view

Analysts rate Tenax Therapeutics Inc a buy (6 buy, 4 hold, 0 sell out of 10) with an average price target of $12.56.

Shareholding

Insiders

0.18%

Institutions

108.50%

Largest institutional holders

Fund	Stake
FMR Inc	10.53%
Vivo Capital, LLC	6.68%
HHG PLC	4.85%
BlackRock Inc	4.62%
Perceptive Advisors LLC	4.54%
Vanguard Capital Management, LLC	3.07%
Millennium Management LLC	2.34%
Ikarian Capital, LLC	2.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tenax Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.